NEW DELHI, 16.08.23-Tulasi Healthcare has introduced innovative dTMS therapy to address Treatment-Resistant Depression (TRD). This non-invasive technique, approved by regulatory authorities like the FDA, aims to provide effective treatment for individuals struggling with TRD. Since its launch in July 2023, Tulasi Healthcare has successfully treated 4 patients, with plans to help 50 patients monthly. Each 20-30 minute session induces neuroplastic changes in specific brain regions, enhancing mood regulation.
Dr. Gorav Gupta, Co-Founder, emphasizes their commitment to compassionate care and personalized treatment plans. Combining dTMS with other therapies, Tulasi Healthcare offers a holistic approach for a successful recovery from TRD.